title: Suicidal ideation and pharmacotherapy among STEP-BD patients.
abstract: OBJECTIVE
  Little is known about the effects of lithium on suicidal ideation or about the possible antisuicidal effects of divalproex, second-generation antipsychotics, or antidepressants among persons with bipolar disorder.
  
  
  METHODS
  Using a cross-sectional design, the authors examined patterns of psychotropic drug use relative to suicidal ideation among 1,000 patients with bipolar disorder in the National Institute of Mental Health's Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).
  
  
  RESULTS
  The presence of suicidal ideation was similar between patients who were taking any lithium and those who were not (22.2 percent and 25.8 percent, respectively) and between those who were taking any divalproex and those who were not (20.3 percent and 21.5 percent). Suicidal ideation was significantly more prevalent among patients who were taking a second-generation antipsychotic than those who were not (26 percent and 17 percent) and those who were taking an antidepressant and those who were not (25 percent and 14 percent). After other variables had been controlled for, lithium prescriptions were significantly more common among patients who had suicidal ideation.
  
  
  CONCLUSIONS
  Among patients with bipolar disorder who have suicidal ideation, antidepressants and second-generation antipsychotics appear to be prescribed by community practitioners more often than other medications, with lithium reserved for those with more severe illness characteristics.
authors.affiliation: Affective Disorders Program, Silver Hill Hospital, 208 Valley Road, New Canaan, Connecticut 06840, and Department of Psychiatry, University of Colorado School of Medicine, Denver, USA. jfgoldberg@yahoo.com
authors.forename: Joseph F
authors.initials: JF
authors.lastname: Goldberg
authors.forename: Michael H
authors.initials: MH
authors.lastname: Allen
authors.forename: David A
authors.initials: DA
authors.lastname: Miklowitz
authors.forename: Charles L
authors.initials: CL
authors.lastname: Bowden
authors.forename: Carrie J
authors.initials: CJ
authors.lastname: Endick
authors.forename: Cheryl A
authors.initials: CA
authors.lastname: Chessick
authors.forename: Stephen R
authors.initials: SR
authors.lastname: Wisniewski
authors.forename: Sachiko
authors.initials: S
authors.lastname: Miyahara
authors.forename: Kemal
authors.initials: K
authors.lastname: Sagduyu
authors.forename: Michael E
authors.initials: ME
authors.lastname: Thase
authors.forename: Joseph R
authors.initials: JR
authors.lastname: Calabrese
authors.forename: Gary S
authors.initials: GS
authors.lastname: Sachs
mesh_terms: D000328:Adult; D000928:Antidepressive Agents / Q000009:adverse effects*; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D018692:Antimanic Agents / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000188:drug therapy*; D015331:Cohort Studies; D005260:Female; D006801:Humans; D008094:Lithium / Q000627:therapeutic use*; D016015:Logistic Models; D008297:Male; D010347:Patient Care Planning; D013405:Suicide / Q000523:psychology* / Q000706:statistics & numerical data; D014481:United States; D014635:Valproic Acid / Q000627:therapeutic use*; D000092864:Suicide Prevention
chemical_list: D000928:Antidepressive Agents; D018687:Antidepressive Agents, Second-Generation; D018692:Antimanic Agents; D014635:Valproic Acid; D008094:Lithium